ORKT Orangekloud reports sharp Q4 2024 EPS miss and 336 percent year over year revenue drop shares unchanged CanopyGrowth CGC Stock Key Growth Drivers 482 20260420 Karman Holdings KRMN Stock Good Opportunity Trend Strengthens 20260422 PGP Pimco posts 587 percent year over year Q3 2025 revenue growth shares climb 033 percent today Regeneron Pharmaceuticals REGN Dupixent Secures FDA Approval as First Biologic for Pediatric Chronic Spontaneous Urticaria Expanding Blockbuster Drugs Addressable Market